Compare $GTBP vs $INAB | Chartloom

Compare

$GTBP vs $INAB

GT Biopharma Inc · IN8bio Inc

GTBP

GT Biopharma Inc

INAB

IN8bio Inc

Compare $GTBP vs $INAB

Comparing GT Biopharma Inc and IN8bio Inc

GTBPGT Biopharma Inc

INABIN8bio Inc

GTBPGT Biopharma Inc

Market cap

$296M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-67.3%

52W performance

-75.3%

FCF yield

-4.9%

INABIN8bio Inc

Market cap

$13M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-45.5%

52W performance

-44.4%

FCF yield

-110.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GTBP

INAB

Detailed metrics comparison

GTBP

GT Biopharma Inc

INAB

IN8bio Inc

Market Cap

GTBP$296M

INAB$13M

Enterprise Value

GTBP$291M

INAB$-5M

Price

GTBP$6.68

INAB$1.34

P/E Ratio

GTBPN/A

INABN/A

P/S Ratio

GTBP174.71x

INAB0.00x

EV/Sales

GTBP95.98x

INAB0.00x

EV/EBITDA

GTBP0.00x

INAB0.00x

P/B Ratio

GTBP3.08x

INAB0.75x

P/FCF Ratio

GTBPN/A

INABN/A

EV/FCF

GTBP-20.19x

INAB0.32x

PEG Ratio

GTBPN/A

INABN/A

Forward P/E (NTM)

GTBPN/A

INABN/A

Forward P/S (NTM)

GTBPN/A

INABN/A

Revenue (TTM)

GTBP$0

INAB$0

Revenue Growth (YoY)

GTBPN/A

INABN/A

Forward Rev Growth

GTBP216.5%

INAB1211.4%

Gross Margin (TTM)

GTBP36.5%

INAB0.0%

Operating Margin (TTM)

GTBP0.0%

INAB0.0%

EBITDA Margin (TTM)

GTBP0.0%

INAB0.0%

Net Margin (TTM)

GTBP0.0%

INAB0.0%

FCF Margin (TTM)

GTBPN/A

INABN/A

Net Income (TTM)

GTBP$-33M

INAB$-19M

FCF (TTM)

GTBP$-14M

INAB$-15M

EPS (TTM)

GTBP-$21.10

INAB-$0.96

ROE (TTM)

GTBP-44308.0%

INAB-9118.0%

ROA (TTM)

GTBP-31311.0%

INAB-7693.0%

ROIC (TTM)

GTBP-44308.0%

INAB-9006.0%

Cash

GTBP$5M

INAB$18M

Debt

GTBP$0

INAB$126K

Net Cash/Debt

GTBP$5M

INAB$18M

Current Ratio (TTM)

GTBP2.61x

INAB8.21x

Quick Ratio (TTM)

GTBP2.51x

INAB8.13x

Debt/Equity (TTM)

GTBP0.00x

INAB0.01x

Debt/Assets (TTM)

GTBP0.0%

INAB0.0%

Interest Coverage (TTM)

GTBPN/A

INABN/A

Net Debt/EBITDA (TTM)

GTBP0.00x

INAB0.00x

Beta

GTBP0.81

INAB0.24

52W Performance

GTBP-75.3%

INAB-44.4%

YTD Performance

GTBP-67.3%

INAB-45.5%

% from 52W High

GTBP-76.8%

INAB-50.9%

% from 52W Low

GTBP36.0%

INAB52.3%

Asset Turnover (TTM)

GTBP0.08x

INAB0.00x

FCF Yield (TTM)

GTBP-4.9%

INAB-110.6%

Earnings Yield (TTM)

GTBP-11.1%

INAB-141.4%

Dividend Yield (TTM)

GTBPN/A

INABN/A

Rule of 40

GTBP0.0

INAB0.0

EV/GP/RG

GTBPN/A

INABN/A

Ticker research

View GTBP research View INAB research

Metric	GTBP GT Biopharma Inc	INAB IN8bio Inc
Market & Valuation
Market Cap	$296M	$13M
Enterprise Value	$291M	$-5M
Price	$6.68	$1.34
P/E Ratio	N/A	N/A
P/S Ratio	174.71x	0.00x
EV/Sales	95.98x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.08x	0.75x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	0.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	216.5%	1211.4%
Profitability
Gross Margin (TTM)	36.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-33M	$-19M
FCF (TTM)	$-14M	$-15M
EPS (TTM)	-$21.10	-$0.96
ROE (TTM)	-44308.0%	-9118.0%
ROA (TTM)	-31311.0%	-7693.0%
ROIC (TTM)	-44308.0%	-9006.0%
Financial Health
Cash	$5M	$18M
Debt	$0	$126K
Net Cash/Debt	$5M	$18M
Current Ratio (TTM)	2.61x	8.21x
Quick Ratio (TTM)	2.51x	8.13x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.81	0.24
52W Performance	-75.3%	-44.4%
YTD Performance	-67.3%	-45.5%
% from 52W High	-76.8%	-50.9%
% from 52W Low	36.0%	52.3%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	0.00x
FCF Yield (TTM)	-4.9%	-110.6%
Earnings Yield (TTM)	-11.1%	-141.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GTBP research	View INAB research

Valuation

P/S Ratio

INAB

0.00x

GTBP

174.71x

EV/FCF

GTBP

-20.19x

INAB

0.32x

Growth & revenue

Forward Revenue Growth

INAB

1211.4%

GTBP

216.5%

Profitability & performance

Gross Margin

GTBP

36.5%

INAB

0.0%

ROE

INAB

-9118.0%

GTBP

-44308.0%

FCF Yield %

GTBP

-4.9%

INAB

-110.6%

52-Week Performance

INAB

-44.4%

GTBP

-75.3%

Detailed metrics comparison

GTBP

GT Biopharma Inc

INAB

IN8bio Inc

Market Cap

GTBP$296M

INAB$13M

Enterprise Value

GTBP$291M

INAB$-5M

Price

GTBP$6.68

INAB$1.34

P/E Ratio

GTBPN/A

INABN/A

P/S Ratio

GTBP174.71x

INAB0.00x

EV/Sales

GTBP95.98x

INAB0.00x

EV/EBITDA

GTBP0.00x

INAB0.00x

P/B Ratio

GTBP3.08x

INAB0.75x

P/FCF Ratio

GTBPN/A

INABN/A

EV/FCF

GTBP-20.19x

INAB0.32x

PEG Ratio

GTBPN/A

INABN/A

Forward P/E (NTM)

GTBPN/A

INABN/A

Forward P/S (NTM)

GTBPN/A

INABN/A

Revenue (TTM)

GTBP$0

INAB$0

Revenue Growth (YoY)

GTBPN/A

INABN/A

Forward Rev Growth

GTBP216.5%

INAB1211.4%

Gross Margin (TTM)

GTBP36.5%

INAB0.0%

Operating Margin (TTM)

GTBP0.0%

INAB0.0%

EBITDA Margin (TTM)

GTBP0.0%

INAB0.0%

Net Margin (TTM)

GTBP0.0%

INAB0.0%

FCF Margin (TTM)

GTBPN/A

INABN/A

Net Income (TTM)

GTBP$-33M

INAB$-19M

FCF (TTM)

GTBP$-14M

INAB$-15M

EPS (TTM)

GTBP-$21.10

INAB-$0.96

ROE (TTM)

GTBP-44308.0%

INAB-9118.0%

ROA (TTM)

GTBP-31311.0%

INAB-7693.0%

ROIC (TTM)

GTBP-44308.0%

INAB-9006.0%

Cash

GTBP$5M

INAB$18M

Debt

GTBP$0

INAB$126K

Net Cash/Debt

GTBP$5M

INAB$18M

Current Ratio (TTM)

GTBP2.61x

INAB8.21x

Quick Ratio (TTM)

GTBP2.51x

INAB8.13x

Debt/Equity (TTM)

GTBP0.00x

INAB0.01x

Debt/Assets (TTM)

GTBP0.0%

INAB0.0%

Interest Coverage (TTM)

GTBPN/A

INABN/A

Net Debt/EBITDA (TTM)

GTBP0.00x

INAB0.00x

Beta

GTBP0.81

INAB0.24

52W Performance

GTBP-75.3%

INAB-44.4%

YTD Performance

GTBP-67.3%

INAB-45.5%

% from 52W High

GTBP-76.8%

INAB-50.9%

% from 52W Low

GTBP36.0%

INAB52.3%

Asset Turnover (TTM)

GTBP0.08x

INAB0.00x

FCF Yield (TTM)

GTBP-4.9%

INAB-110.6%

Earnings Yield (TTM)

GTBP-11.1%

INAB-141.4%

Dividend Yield (TTM)

GTBPN/A

INABN/A

Rule of 40

GTBP0.0

INAB0.0

EV/GP/RG

GTBPN/A

INABN/A

Ticker research

View GTBP research View INAB research

Metric	GTBP GT Biopharma Inc	INAB IN8bio Inc
Market & Valuation
Market Cap	$296M	$13M
Enterprise Value	$291M	$-5M
Price	$6.68	$1.34
P/E Ratio	N/A	N/A
P/S Ratio	174.71x	0.00x
EV/Sales	95.98x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.08x	0.75x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	0.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	216.5%	1211.4%
Profitability
Gross Margin (TTM)	36.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-33M	$-19M
FCF (TTM)	$-14M	$-15M
EPS (TTM)	-$21.10	-$0.96
ROE (TTM)	-44308.0%	-9118.0%
ROA (TTM)	-31311.0%	-7693.0%
ROIC (TTM)	-44308.0%	-9006.0%
Financial Health
Cash	$5M	$18M
Debt	$0	$126K
Net Cash/Debt	$5M	$18M
Current Ratio (TTM)	2.61x	8.21x
Quick Ratio (TTM)	2.51x	8.13x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.81	0.24
52W Performance	-75.3%	-44.4%
YTD Performance	-67.3%	-45.5%
% from 52W High	-76.8%	-50.9%
% from 52W Low	36.0%	52.3%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	0.00x
FCF Yield (TTM)	-4.9%	-110.6%
Earnings Yield (TTM)	-11.1%	-141.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GTBP research	View INAB research